Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer
This article was originally published in The Tan Sheet
Executive Summary
Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany
You may also be interested in...
Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains
Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27
Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains
Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27
Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains
Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: